Form 4: Vistagen Therapeutics CFO Reports Future Share Acquisition via Employee Stock Purchase Plan

Vistagen Therapeutics' Chief Financial Officer, Cynthia Lynn Anderson, has reported a future acquisition of 6,617 shares of common stock at $1.70 per share through the company's Employee Stock Purchase Plan, effective June 30, 2025.

Summary

• Cynthia Lynn Anderson, Chief Financial Officer of Vistagen Therapeutics, Inc. (VTGN), is set to acquire 6,617 shares of common stock.
• The acquisition is scheduled for June 30, 2025, at a price of $1.70 per share.
• This transaction is being conducted under the Issuer's 2019 Employee Stock Purchase Plan, as amended.
• Following this acquisition, Cynthia Lynn Anderson will beneficially own a total of 12,801 shares of Vistagen Therapeutics common stock.
• The transaction is exempt from certain reporting requirements under Rule 16b-3(c) and Rule 16b-3(d) of the Securities Exchange Act of 1934.

Sentiment

Score: 6

Explanation: The acquisition of shares by a CFO, even through an ESPP, generally indicates a positive alignment of interests and confidence in the company. However, it is a pre-planned, non-discretionary transaction, which limits its immediate market signal strength compared to an open-market purchase.

Positives

• Insider acquisition of shares, even through an Employee Stock Purchase Plan (ESPP), can signal management's confidence in the company's future prospects.
• Participation in the Employee Stock Purchase Plan aligns the financial interests of the Chief Financial Officer with those of shareholders, promoting shared objectives.

Negatives

• The transaction date of June 30, 2025, is in the future, indicating a pre-planned acquisition rather than a discretionary open-market purchase based on immediate market conditions, which may limit its signal of current management sentiment.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: The CFO's increased ownership aligns her interests with those of shareholders, potentially fostering greater confidence in management's commitment to long-term value creation.

Key Dates

Keywords

Vistagen Therapeutics, VTGN, Cynthia Lynn Anderson, Chief Financial Officer, Form 4, SEC filing, insider transaction, stock acquisition, Employee Stock Purchase Plan, ESPP, common stock, beneficial ownership